Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide new treatment options for rare, aggressive cancers, including anaplastic thyroid cancer (ATC), glioblastoma, leptomeningeal disease (LMD) and soft-tissue sarcomas. For most of these rare diseases, survival is poor and few – if any – effective treatment options are currently available.
As...
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...
“Trainees at the Ph.D. and postdoctoral level are leaving the academic research track at alarming rates, and disproportionately if they’re...
While U.S. cervical cancer rates have fallen by 70% since the 1950s thanks to the Pap test and national screening programs, the disease remains a leading killer of women in low- and middle-income countries for lack of access to screening and trained providers.
Kathleen Schmeler, M.D., professor of Gynecologic Oncology and Reproductive Medicine, is working change this. Her work to prevent and treat cervical cancer has taken...
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...